Preface – ASCO 2016
Paul A. Bunn Jr., MD, FASCO, Distinguished Professor and James Dudley Chair of Lung Cancer Research, University of Colorado Cancer Center, Aurora, Colorado, USA. 2016 David A. Karnofsky Memorial Award Winner
Dear Colleagues,
Lung cancer mortality rates for both men and women have been declining in recent years. Early detection, refined understanding of tumour biology, and a variety of novel treatment options have made these advances possible. Nevertheless, lung cancer is still the leading cause of cancer death in the United States and worldwide, prompting the scientific community to persevere in their research efforts and to extend them to areas that have traditionally been marked by little progress, such as small-cell lung cancer (SCLC).
At the Annual Meeting of the American Society of Clinical Oncology (ASCO) that took place in Chicago, 3rd–7th June, 2016, promising results were presented that have been achieved using immunotherapeutic approaches in the setting of SCLC. As in non-SCLC (NSCLC), it appears that a certain proportion of treated patients can hope for long-term survival. Also, phase I data on the DLL3-targeted antibody–drug conjugate rovalpituzumab tesirine suggest that it has clinically relevant activity in the SCLC population.
One quarter of the abstracts submitted for this year’s ASCO Congress were focussed on the topic of immunotherapy. According to updates of pivotal trials, sustained benefits can be expected in a minority of patients with these drugs. Combination immunotherapy consisting of nivolumab and ipilimumab may provide benefits over nivolumab monotherapy in advanced NSCLC of any histology. However, molecularly targeted therapies remain the preferred therapeutic choice in the first line for patients with driver alterations. ALK inhibitors such as alectinib and brigantinib have shown efficacy in tumours with ALK-resistance mutations, and the novel agents lorlatinib and olmutinib are being tested in ALK/ROS1– positive and EGFR-T790M-mutated NSCLC, respectively.
Continual refinement in the field of molecular diagnostics is a cornerstone of this evolution. According to a large analysis, targeted therapy conferred survival improvements when all driver mutations were considered. Minimally invasive techniques are gaining ground, due to their obvious advantages. The assessment of circulating tumour DNA, which is obtained through conventional blood sampling, enables profiling of solid tumours and adds to the accuracy of tissue typing.
More posts
PFS improvement due to local therapy in oligometastatic NSCLC
Evidence suggests the existence of a ,limited metastatic’ NSCLC phenotype. However, the type of optimal treatment and the role of aggressive local therapy in these patients remain controversial. Gomez et al. presented the first prospective, randomised trial to address this question. Patients had stage IV disease without RECIST progression and a maximum of three metastases after front-line systemic therapy (FLST).
Locally advanced NSCLC: oral vinorelbine shows better safety profile than etoposide
The randomised, multicentre, open-label, phase II RENO trial was conducted with the objective of establishing a standard chemotherapy regimen in the setting of chemo-radiotherapy of locally advanced NSCLC. A total of 134 patients with inoperable stage III NSCLC received either oral vinorelbine plus cisplatin or etoposide plus cisplatin.
ULTIMATE: chemotherapy plus bevacizumab beyond first line
As chemotherapy in the second-line or third-line settings of NSCLC shows limited efficacy, the phase III, randomised ULTIMATE trial tested the combination of chemotherapy and bevacizumab in patients with advanced NSCLC of non-squamous histology, who had progressed after one or two lines of treatment.
New approaches are raising hope for SCLC patients
Only minor progress has been made over the past 30 to 40 years in the treatment of small-cell lung cancer (SCLC), which accounts for 10 % to 15 % of lung cancer cases. SCLC is radiosensitive, but approximately 70 % of patients present with extended disease that cannot be included within one radiotherapy field. The majority of patients respond to first-line chemotherapy.
Mutational analysis: on the road to refined standards
The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional consortium for the study of driver mutations of lung adenocarcinoma. The cooperating sites enable the identification of relatively large numbers of patients with uncommon and rare alterations, facilitate the analysis of their clinical characteristics, and lay the ground for targeted therapy trials.
“The importance of first-line and second-line targeted agents is obvious”
Which parameters should be taken into consideration regarding the choice of EGFR TKIs in a lung cancer patient with an activating EGFR mutation? When EGFR mutations are diagnosed in the first-line setting, we have the luxury of having three options today. However, it is important to discriminate between the different types.
